[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
    "title": "Kvartalsrapport Q2 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a8b00b947a5558a7cef2b0564a7b70cac",
    "date": "2026-07-17",
    "period": "2026-q2",
    "form_type": "interim-report",
    "report_key": "2026:q2",
    "filename": "Xbrane_Q2_2026_SVE_Final.pdf",
    "text_chars": 51755,
    "sha256": "7e3d3748b4c0f10fcbf22c4cb67faf9669e1483be41ef2ce36e7b6f44414b2d3",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
        "chars": 51755
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/acc297eb055190ad3b4286e211b143166",
    "date": "2026-05-05",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "Xbrnane_Q1_2026_SVE_Final.pdf",
    "text_chars": 45705,
    "sha256": "357f9101e71e4b40226b094761e2e48c3bf75479d1e9ee875639dd80adf3ccf2",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 45705
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a9d342a40ad1e12dc500324a338e7209f",
    "date": "2026-03-31",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "Xbrane_AR_2025.pdf",
    "text_chars": 343429,
    "sha256": "fa1e0f6252dbc314c29334cc9f47339e138eda9fe1bbb323c6b6604635fdec75",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 174293
      },
      {
        "number": 2,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 169134
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a813f72aa1fe1d92f6a7849f53ce18fb2",
    "date": "2026-02-20",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "Xbrane_Q4_2025_SV_Final.pdf",
    "text_chars": 52117,
    "sha256": "ccb9f087648165009e342257f1663f96082a2f50d5602cc0c5b9c88137520dd3",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 52117
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ae3a7879bcb3b8d96fb5b9d491e2691eb",
    "date": "2025-10-24",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "Xbrane_Biopharma_Publicerar_Delarsrapport_Januari_September_2025.pdf",
    "text_chars": 53374,
    "sha256": "088aab35dd2d493f1f1dd6900780ae3ccef45d7ecea2df6a44e3e6f956d86223",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 53374
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a8b28a04292205e718386a24bd65b425b",
    "date": "2025-08-26",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "Xbrane_Delarsrapport_Januari_Juni_2025.pdf",
    "text_chars": 49294,
    "sha256": "5ff496ee4d1781dd51924b3e53802d929b304b3523e29dad66af759ae0b29ee5",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 49294
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a8c392a9c26ea21acb0666e12bd29d58c",
    "date": "2025-05-08",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "Xbrane_Delarsrapport_Januari_Mars_2025.pdf",
    "text_chars": 44399,
    "sha256": "eebeffba94a890e55b83e3e31b6dae3ec4451ccb469e83db1504d24f6113b139",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 44399
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a7eef0a3ebf43923dd5572e56af90417c",
    "date": "2025-03-31",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "Xbrane_Ars_Och_Hallbarhetsredovisning_2024.pdf",
    "text_chars": 325763,
    "sha256": "3f5b5f0e1147f37150907444d67397d2b022ad57ad5be6e7ce0829c99f5313c9",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 178810
      },
      {
        "number": 2,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
        "chars": 146951
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a4d584d783c99dfbd00656a582f145aed",
    "date": "2025-02-20",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "Bokslutskommunike_2024_Xbrane_Biopharma.pdf",
    "text_chars": 66354,
    "sha256": "fabc4c3f648bfaae047c5f1794f2dc75e25771d6b0a6e15aa604843f962b1f70",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 66354
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a8adcf2134633ef76ecaee3beb2b2afd3",
    "date": "2024-10-24",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "Xbrane_Delarsrapport_Januari_September_2024.pdf",
    "text_chars": 64031,
    "sha256": "fea7b56153d5e34d2498ca1265ed60625b390a87c8eaa9af74ea8fe81a6f0601",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 64031
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/afcd1197113fc2b33e83865f022b318ab",
    "date": "2024-08-28",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "Xbrane_Delarsrapport_Januari_Juni_2024.pdf",
    "text_chars": 64019,
    "sha256": "13bfd4d1ca17750edb29ab5cf61d779d4e5b6e69751a3c38c3bd16f89e071875",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 64019
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
    "title": "Kvartalsrapport Q1 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/af09b23e96b28bf344d5899d50a74609a",
    "date": "2024-05-16",
    "period": "2024-q1",
    "form_type": "interim-report",
    "report_key": "2024:q1",
    "filename": "Xbrane_Delarsrapport_Januari_Mars_2024.pdf",
    "text_chars": 60276,
    "sha256": "f6d05051c23488cb563c691d05a2d6defeec9d034c1b584f3e6cd4eecfea6e12",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
        "chars": 60276
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2023",
    "title": "Årsredovisning 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a6856e0b392caa7dc1b69afb9788317fd",
    "date": "2024-03-27",
    "period": "2023-annual",
    "form_type": "annual-report",
    "report_key": "2023:annual",
    "filename": "Ars_Och_Hallbarhetsredovisning_2023_Xbrane_Biopharma_AB.pdf",
    "text_chars": 350135,
    "sha256": "f2c82c155bbcd60f120feda5cb54d6785c0f8d90179e7d9d4bccd9c089063e8d",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
        "chars": 178430
      },
      {
        "number": 2,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
        "chars": 171703
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
    "title": "Kvartalsrapport Q4 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/aae2c3aebe98040e16efe5e5bf4419283",
    "date": "2024-02-26",
    "period": "2023-q4",
    "form_type": "year-end-report",
    "report_key": "2023:q4",
    "filename": "Xbrane_Bokslutskommunike_2023.pdf",
    "text_chars": 62036,
    "sha256": "3c0e145ce0ae8ac70264c1582c7127997cae57c2f4d7cc2236db75b7ba49f513",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
        "chars": 62036
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
    "title": "Kvartalsrapport Q3 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/abc62f12149e6042fbd3d0330700058f6",
    "date": "2023-11-30",
    "period": "2023-q3",
    "form_type": "interim-report",
    "report_key": "2023:q3",
    "filename": "Xbrane_Delarsrapport_Janari_September_2023.pdf",
    "text_chars": 65523,
    "sha256": "b50e5ff5fcedba001dd13b6125e935ddba56e6a47f92c9aacc5eacf1abf426df",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
        "chars": 65523
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
    "title": "Kvartalsrapport Q2 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a69952714f15e9944fee6cea540351063",
    "date": "2023-08-29",
    "period": "2023-q2",
    "form_type": "interim-report",
    "report_key": "2023:q2",
    "filename": "Xbrane_Delarsrapport_Januari_Juni_2023.pdf",
    "text_chars": 67811,
    "sha256": "3bc9b51984690eb69acda822fed28ad70573c71682bb3fdf177c9f11c46934dd",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
        "chars": 67811
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
    "title": "Kvartalsrapport Q1 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a7e48fde7152361f229b91537d0dfb244",
    "date": "2023-05-31",
    "period": "2023-q1",
    "form_type": "interim-report",
    "report_key": "2023:q1",
    "filename": "Xbrane_Delarsrapport_Januari_Mars_2023.pdf",
    "text_chars": 62648,
    "sha256": "cd9946c616fd15ef5bca6abaaf5a535bf592b856e067f4f2d356e83adff960d0",
    "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "txt_url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
        "chars": 62648
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/xbrane-biopharma",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 14274,
    "sha256": "75018dbea8a03a04cf8a7bd2996953ebb3288c2ff099ae360c6c7e14ff7ad666",
    "url": "/company/xbrane-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/xbrane-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/xbrane-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/xbrane-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/xbrane-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 14274
      }
    ]
  }
]